Disease · HP_0000613
Photophobia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Photophobia. Diseases, record HP_0000613. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000613
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Photophobia
- Open Targets ID
- HP_0000613
- Other names
- Extreme sensitivity of the eyes to light, Light hypersensitivity, Photodysphoria
- Highest stage of its drugs
- Phase 3, for 1 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SUMATRIPTAN | CHEMBL128 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYSTEAMINE | CHEMBL602 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GABAPENTIN | CHEMBL940 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYALURONIC ACID | CHEMBL5314376 | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| RIBOFLAVIN | CHEMBL1534 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1A | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/773 | Drugs and targets |
| CACNA1B | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/774 | Drugs and targets |
| CACNA1C | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1E | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/777 | Drugs and targets |
| CACNA1F | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1G | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/8913 | Drugs and targets |
| CACNA1H | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/8912 | Drugs and targets |
| CACNA1I | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/8911 | Drugs and targets |
| CACNA1S | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Unknown | https://conductscience.org/library/genes/779 | Drugs and targets |
1 to 10 of 29
See all 29 targetsTrials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00724815 | The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine | Phase 3 | 530 | 2013-05-07 | Migraine Disorders | SUMATRIPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT06293300 | Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A) | Phase 2 | 50 | Traumatic Brain Injury | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov | |
| NCT02766855 | Efficacy of Topical Cysteamine in Nephropathic Cyctinosis | Not applicable | 26 | Nephropathic Cyctinosis, Corneal Cystine Crystals | CYSTEAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06122428 | Efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops in Treating Dry Eye Disease | 16 | Dry Eye Disease | HYALURONIC ACID | Its record names the disease | ClinicalTrials.gov | ||
| NCT04345432 | Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS) | Not applicable | 10 | Postural Orthostatic Tachycardia Syndrome | GABAPENTIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NP101 Patch vs Placebo Patch: serious adverse events | 0 of 234 | 0 of 235 | 469 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Photophobia Free at Two Hours | 116 of 226 | 83 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Pain Free at Two Hours | 40 of 226 | 21 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Nausea Free at Two Hours | 189 of 226 | 144 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Phonophobia Free at Two Hours | 125 of 226 | 89 of 228 | 454 | NCT00724815 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000613
GET https://conductscience.org/api/diseases/v1/HP_0000613/targets?page=2